A conflict of interest? Mylan executive under fire for 400% EpiPen price hike

Since pharmaceutical company Mylan acquired and began selling EpiPen nearly 10 years ago, the drug's price has spiked almost 400 percent, leading the company's CEO to come under intense scrutiny, according to The New York Times.

Interestingly enough, Heather Bresch, Mylan's chief executive, is the daughter of Sen. Joy Manchin III (D-W.V.). The familial relation could pose as a conflict of interest if the Senate calls on Ms. Beech to testify about the product's price hike.

One senator calling for the executive's testimony claims her family connection will not impact the Senate hearing. Rather, Sen. Richard Blumenthal (D-Conn.) said the Senate would focus on whether Mylan acted immorally with families paying erroneous prices for a life-saving drug that combats allergies.

This week, the Senate Special Committee on Aging required Mylan to provide information and a briefing about the rationale behind the price jump. Democratic presidential candidate referred to the 400 percent price hike at "outrageous." In a statement, Mylan said the company was putting forth efforts to help access to EpiPens such as giving schools free doses of the drug and helping customers with high deductibles pay for EpiPen.

More articles on quality & infection control:
National Patient Safety Foundation updates Online Patient Safety Curriculum: 6 points
NewYork-Presbyterian/Queens launches HIV, HBV and HCV testing initiative for ambulatory care, ED patients: 4 things to know
The need for effective infection & outcome metrics to propel the ASC industry forward

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 


Patient Safety Tools & Resources Database

Featured Webinars

Featured Whitepapers